Smart Investing: Precision Oncology as an Investment Theme at Eventide Funds

Smart Investing: Precision Oncology as an Investment Theme at Eventide Funds

by Mike Jette on May 6, 2019

Lung cancer is a huge unmet medical need. There are over 200,000 new cases per year and it's the number one killer in terms of cancer. 150,000 deaths per year in the United States alone.

Precision oncology is analogous to the comparison between a B-52 bomber and a laser-guided missile. The old way of treating cancer involved chemotherapy. Chemotherapy has significant collateral damage and lower efficacy due to increased toxicity. Unlike chemotherapy, precision oncology offers higher efficacy due to better target coverage. That's analogous to using a laser guided missile to hit a target while avoiding collateral damage.

This is what value creation in biotechnology looks like … longer life and improved quality of life, and reduced cost.

 

We believe it's smart to have conviction about the companies you own, so that you can be proud of what you're doing, and you can be glad that you are advancing the global common good.